Genetic muscular dystrophy - Symptoms, Causes, Treatment & Prevention

```html

Overview

Genetic muscular dystrophy (MD) refers to a group of inherited disorders characterized by progressive weakness and loss of muscle mass. Over 30 distinct types have been identified, each linked to mutations in specific genes that encode proteins essential for muscle fiber stability and repair.

• Who it affects: All ages and sexes can be affected, but the age of onset and severity vary widely among sub‑types. Duchenne muscular dystrophy (DMD), the most common form, primarily affects boys and usually appears before age 5. Other forms, such as Myotonic Dystrophy type 1 (DM1), may present in adulthood and affect both males and females.
• Prevalence: Collectively, muscular dystrophies affect roughly 1 in 3,500–5,000 live births worldwide. DMD accounts for ~60 % of all cases (≈1 in 3,500 male births) [1], while Becker muscular dystrophy (BMD) occurs in about 1 in 18,000 male births [2].

Because the root cause is a genetic mutation, MD is not contagious, and standard infection‑control measures are unnecessary.

Symptoms

Symptoms differ by MD subtype, but common features include:

• Muscle weakness: Typically starts in the proximal muscles (hips, shoulders) and spreads distally. In DMD, the gait becomes waddling; in facioscapulohumeral dystrophy (FSHD), facial and shoulder muscles are first affected.
• Muscle wasting (atrophy): Visible thinning of limbs, especially calves in DMD (“pseudohypertrophy”).
• Difficulty rising from the floor, climbing stairs, or lifting objects.
• Joint contractures: Permanent tightening of muscles/tendons, often causing a “Gowers’ sign” where the child uses hands to climb up the thighs to stand.
• Respiratory problems: Weakness of diaphragm and intercostal muscles leads to reduced lung capacity and frequent infections.
• Cardiac involvement: Dilated cardiomyopathy or arrhythmias, especially in DMD/BMD.
• Myotonia: Delayed muscle relaxation after contraction (characteristic of DM1/DM2).
• Facial and ocular manifestations: Ptosis, cataracts, or retinal changes in certain sub‑types (e.g., oculopharyngeal MD).
• Gastrointestinal issues: Difficulty swallowing (dysphagia) and constipation due to smooth‑muscle involvement.
• Fatigue and exercise intolerance.
• Developmental delays: In severe forms like DMD, motor milestones may be delayed.

Symptoms usually progress slowly over years, but the rate varies: DMD patients often lose ambulation by age 12‑14, whereas individuals with limb‑girdle MD may retain walking ability into adulthood.

Causes and Risk Factors

Genetic Basis

MD results from mutations that alter structural proteins of the muscle cell membrane (sarcolemma) or proteins involved in nuclear function. The most common genes include:

• DMD gene (dystrophin): Mutations cause DMD or BMD.
• CAAT‑box binding transcription factor (CCT) genes: Mutations lead to myotonic dystrophy.
• FKRP, SGCA, SGCB, SGCD, SGCG: Associated with various limb‑girdle MD sub‑types.
• DYSF (dysferlin): Causes dysferlinopathy (Miyoshi muscular dystrophy).

Inheritance Patterns

• X‑linked recessive: DMD and BMD; primarily affect males; females are carriers.
• Autosomal dominant: Myotonic dystrophy, FSHD, oculopharyngeal MD.
• Autosomal recessive: Many limb‑girdle MDs, sarcoglycanopathies, dysferlinopathy.

Risk Factors

• Having an affected parent or sibling.
• Carrier status (especially for X‑linked forms).
• Consanguineous marriage increases risk for recessive forms.
• No lifestyle factors directly cause MD, but sedentary behavior can worsen functional decline.

Diagnosis

Diagnosing genetic muscular dystrophy involves a combination of clinical evaluation, laboratory testing, imaging, and genetic analysis.

Clinical Evaluation

• Detailed history (family pedigree, age of onset, progression pattern).
• Physical exam focusing on muscle strength (Medical Research Council scale), tone, reflexes, and contractures.

Laboratory Tests

• Creatine kinase (CK) level: Often markedly elevated (10‑50× normal) in early disease.
• Serum aldolase, lactate dehydrogenase, and transaminases may also be raised.

Imaging

• Muscle MRI: Detects fatty infiltration and pattern‑specific changes; useful for monitoring progression.
• Ultrasound: Portable alternative for assessing muscle thickness.

Electrophysiology

• Electromyography (EMG): Shows myopathic changes (short duration, low amplitude motor units).
• Nerve conduction studies: Typically normal, helping differentiate from neuropathies.

Genetic Testing

Definitive diagnosis rests on identifying the pathogenic mutation:

• Targeted gene panels (most common MD genes) – cost‑effective and rapid.
• Whole‑exome or whole‑genome sequencing for atypical presentations.
• Multiplex ligation‑dependent probe amplification (MLPA) to detect large deletions/duplications in the DMD gene.

Genetic counseling is recommended for patients and at‑risk relatives.

Treatment Options

Currently there is no cure for most genetic muscular dystrophies, but multidisciplinary care can slow progression, manage complications, and improve quality of life.

Pharmacologic Therapies

• Corticosteroids (prednisone, deflazacort): First‑line in DMD; delay loss of ambulation by 2‑3 years and improve pulmonary function [3].
• Exon‑skipping agents (eteplirsen, golodirsen, viltolarsen): FDA‑approved for subsets of DMD patients with specific exon deletions; aim to produce a shortened but functional dystrophin.Gene‑replacement (AAV‑mediated micro‑dystrophin): Ongoing Phase III trials show promising increases in dystrophin expression and functional gains.
• Antifibrotic/anti‑inflammatory drugs: Trials with vamorolone and tamoxifen are exploring reduced side‑effects compared with steroids.
• Cardiac medications: ACE inhibitors, beta‑blockers, and mineralocorticoid receptor antagonists to treat cardiomyopathy.
• Respiratory agents: Long‑term non‑invasive ventilation (BiPAP) and, when needed, cough‑assistance devices.

Physical and Occupational Therapy

• Stretching programs to prevent contractures.
• Low‑impact aerobic exercise (e.g., swimming, stationary cycling) to maintain endurance while minimizing muscle damage.
• Assistive devices (orthoses, walkers, wheelchairs) tailored to disease stage.
• Occupational therapy for adaptive equipment (e.g., reachers, modified utensils).

Surgical Interventions

• Scoliosis correction (spinal fusion) when curvature exceeds 30–40°.
• Tendon releases or lengthening procedures to address severe contractures.
• Cardiac device implantation (pacemaker, implantable cardioverter‑defibrillator) for arrhythmias.

Lifestyle & Supportive Measures

• Nutrition: High‑protein, calorie‑dense diet; consider supplements (vitamin D, calcium) for bone health.
• Regular pulmonary assessments; vaccination against influenza and pneumococcus.
• Psychological support: counseling, support groups, and educational accommodations.

Living with Genetic Muscular Dystrophy

Daily Management Tips

1. Morning stretching routine: 10‑15 minutes focusing on hip flexors, hamstrings, and shoulder girdle to maintain range of motion.
2. Energy conservation: Plan activities in short, frequent bouts; use adaptive equipment to reduce fatigue.
3. Monitor respiratory function: Perform daily peak‑flow or cough‑assist checks; keep a portable suction device if recommended.
4. Heart health vigilance: Record heart rate and any palpitations; attend cardiology follow‑up every 6–12 months.
5. Skin care: Prevent pressure sores by repositioning and using cushions; inspect skin daily.
6. Medication adherence: Use pill organizers or reminder apps; discuss steroid side‑effects (weight gain, bone loss) with your doctor.
7. Stay connected: Join MD patient organizations (Muscular Dystrophy Association, Parent Project) for resources and peer support.

Education & Employment

• Request individualized education plans (IEPs) or 504 accommodations for school.
• Employers may provide ergonomic workstations, flexible hours, or remote‑work options under the Americans with Disabilities Act (ADA).

Prevention

While the genetic mutations themselves cannot be prevented, risk can be reduced through informed family planning:

• Carrier screening: Recommended for women with a family history of X‑linked MD or for couples considering pregnancy.
• Pre‑implantation genetic diagnosis (PGD): Allows selection of embryos without the pathogenic mutation during in‑vitro fertilization.
• Prenatal testing: Chorionic villus sampling or amniocentesis can detect known familial mutations.
• Genetic counseling: Provides education about inheritance patterns, recurrence risk, and reproductive options.

There is no evidence that diet, exercise, or environmental exposures prevent the onset of genetic MD.

Complications

If left untreated or inadequately managed, muscular dystrophy can lead to serious health problems:

• Severe respiratory failure: Recurrent infections, atelectasis, and eventual need for invasive ventilation.
• Cardiomyopathy & arrhythmias: Leading cause of mortality in DMD/BMD.
• Progressive scoliosis: Impairs breathing and sitting balance.
• Joint contractures and deformities: May require surgical release.
• Osteoporosis/fractures: Steroid use and reduced mobility increase bone loss.
• Psychosocial issues: Depression, anxiety, and social isolation.
• Renal or hepatic complications: Rare but reported with certain experimental therapies.

When to Seek Emergency Care

---

**References**

1. Mayo Clinic. Duchenne muscular dystrophy – Symptoms and causes. https://www.mayoclinic.org. Accessed May 2026.
2. Cleveland Clinic. Becker muscular dystrophy. https://my.clevelandclinic.org. Accessed May 2026.
3. Bushby K, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. *Lancet Neurology*. 2010;9(1):77‑93.
4. National Institute of Neurological Disorders and Stroke. Muscular Dystrophy Information Page. https://www.ninds.nih.gov. Accessed May 2026.
5. World Health Organization. Genetic disorders: an overview. *WHO Fact Sheet*. 2022.

```